During the past decade, Ashford Cancer Centre Research conducted 56 clinical trials. In the 10-year time frame, 56 clinical trials started and 29 clinical trials were completed, i.e. on average, 51.8% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 18 clinical trials were completed. i.e. 78.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ashford Cancer Centre Research" #1 sponsor was "Hoffmann-La Roche" with 16 trials, followed by "Pfizer" with 8 trials sponsored, "BeiGene" with 5 trials sponsored, "Gilead Sciences" with 4 trials sponsored and "Eli Lilly and Company" with 4 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ashford Cancer Centre Research" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Astellas Pharma Inc" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 3 trials as a collaborator and "Novotech (Australia) Pty Limited" with 3 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Ashford Cancer Centre Research" are "Breast Cancer" (7 trials), "Renal Cell Carcinoma" (7 trials), "Prostate Cancer" (4 trials), "Metastatic Breast Cancer" (3 trials) and "Advanced or Metastatic Solid Tumors" (2 trials). Many other conditions were trialed in "Ashford Cancer Centre Research" in a lesser frequency.

Most popular intervention types in "Ashford Cancer Centre Research" are "Drug" (70 trials), "Other" (8 trials), "Biological" (5 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Atezolizumab" (7 trials), "Paclitaxel" (6 trials), "Rituximab" (6 trials) and "Bevacizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Ashford Cancer Centre Research" are 61 trials for "All" genders, 10 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are 33 active trials in "Ashford Cancer Centre Research". 1 are not yet recruiting, 15 are recruiting, 16 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 34 completed trials in Ashford Cancer Centre Research, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Ashford Cancer Centre Research, 18 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".